Transarterial chemoembolisation-based combination therapy as a potential new standard for intermediate-stage hepatocellular carcinoma in the targeted immunotherapy era
Shuanggang Chen, Lujun Shen, Han Qi, Pan Hu, Fei Cao, Lin Xie, Yujia Wang, Weijun Fan · 2026
Read Transarterial chemoembolisation-based combination therapy as a potential new standard for intermediate-stage hepatocellular carcinoma in the targeted immunotherapy era by Shuanggang Chen, Lujun Shen, Han Qi, Pan Hu, Fei Cao, Lin Xie, Yujia Wang, Weijun Fan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13150888.txt.
Description
Shuanggang Chen and co-authors argue for a new standard in mid-stage liver cancer care in a 2026 review paper. The standard treatment threads chemotherapy into the tumor's artery and blocks it, a method called TACE. Two big trials recently showed that adding targeted and immune drugs stretches the time before tumors grow. Survival gains, though, were uneven between the trials.
The authors sort patients by tumor load, liver strength, vessel invasion, and immune state. Light cases may do best with refined local therapy alone. Heavy cases need the full mix of artery treatment plus drugs. Vessel invasion calls for added targeted pills after the artery work. Sorting first, they argue, turns a mixed trial record into clear bedside rules.
Catalog record
| CREATOR | Shuanggang Chen, Lujun Shen, Han Qi, Pan Hu, Fei Cao, Lin Xie, Yujia Wang, Weijun Fan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |